I-SciSparc Ltd., i-specialty, inqanaba leklinikhi yenkampani yonyango egxile ekuphuhliseni unyango ukunyanga ukuphazamiseka kwenkqubo ye-nervous central, namhlanje ibhengeze ukwakhiwa okujoliswe kuyo kwi-joint venture ("JV") ukugxila ekufumaneni nasekuphuhliseni izinto ezinokubakho. amachiza omhlaza kunye nezinye iimeko ezibeka ubomi esichengeni. Ngaphantsi kwemigaqo ye-JV, ukukhuthaza le njongo, i-SciSparc iya kuseka inkampani entsha yokufumanisa iziyobisi, i-MitoCareX Bio Ltd., i-Israel corporation ("MitoCareX Bio").
I-JV iya kugxila ekuphandeni abathwali be-mitochondrial, iiprotheyini zothutho ezibalulekileyo ekusebenzeni kweeseli. Ngenxa yendima ebalulekileyo yabathwali bemitochondrial ekuthuthweni kweemetabolites eziyimfuneko ekusebenzeni kweeseli kwiinwebu zemitochondrial, iNkampani ikholelwa ukuba iimeko ezahlukeneyo ezibeka ubomi esichengeni, ezifana nomhlaza kunye nezifo ezinqabileyo zemitochondrial, zinokunyangwa ngokulawula umsebenzi wabathwali bemitochondrial. Ebantwini, usapho lomthwali we-mitochondrial (I-Solute Carrier Family 25, SLC25) inamalungu angama-53 kwaye lolona sapho luninzi lwabathuthi.
“Eli lithuba elichulumancisayo elinokubakho ngakumbi ukwandisa umbhobho wethu kwiimpawu ezininzi ezintsha ezijolise kwiimfuno zonyango ezingafezekiyo,” utshilo u-Oz Adler, iGosa eliyiNtloko lesiGqeba kunye neGosa eliyiNtloko lezeziMali le-SciSparc. "I-MitoCareX Bio ijonge ukusebenzisa amandla okufunyanwa kweziyobisi esekwe kwikhompyuter, ikhulisa amava ophando kunye nolwazi oluthile entsimini, ukufumanisa kunye nokuphuhlisa umbhobho onokuthi ubandakanye iimolekyuli ezincinci ezijolise kwiiproteni ezinomdla kwiimeko ezahlukeneyo ezisongela ubomi."
Ukwenza i-JV, i-SciSparc iya kuseka inkampani entsha yokufumanisa iziyobisi, i-MitoCareX Bio Ltd. ("MitoCareX Bio"). Ngokusekelwe kwimiba eqingqwe kwangaphambili, i-SciSparc iya kutyala imali ukuya kuthi ga kwi-1.7 yezigidi zeedola, ukuya kuthi ga kwi-50.01 yepesenti yobunini, kwi-MitoCareX Bio kwiminyaka emibini ezayo kwaye ngokuhambelana nenani leentshukumo ekuvunyelwene ngazo kwisivumelwano. Uphando olutsha lweMitoCareX Bio luya kwakha ngokuyinxenye phezu kovavanyo oluyimpumelelo lwengqikelelo olwenziwe e-UK. UNjingalwazi uCiro Leonardo Pierri (iYunivesithi yaseBari, eItali), ingcali yehlabathi jikelele kwimitochondrial carrier proteins, ubonise kwiNkampani ukuba uzimisele ukuxhasa inkqubo njengomcebisi kwiNkampani.
INTO ONOKUYITHATHA KWELI NQAKU:
- , a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture (“JV”) to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions.
- Professor Ciro Leonardo Pierri (University of Bari, Italy), a global expert in the field of mitochondrial carrier proteins, has indicated to the Company that he intends to support the program as a consultant to the Company.
- “MitoCareX Bio intends to employ computationally-based drug discovery capabilities, leveraging vast research experience and specific knowledge in the field, to discover and potentially develop a pipeline that may include small molecules targeting the proteins of interest in various life-threatening conditions.
